Phase II Study of Cladribine Plus Low Dose Cytarabine (LDAC) Induction Followed By Consolidation With Cladribine Plus LDAC Alternating With Decitabine in Patients With Untreated Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Phase of Trial: Phase II
Latest Information Update: 07 Mar 2018
At a glance
- Drugs Cladribine (Primary) ; Cytarabine (Primary) ; Decitabine (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Therapeutic Use
- 15 Feb 2018 Planned End Date changed from 1 Feb 2019 to 1 Feb 2021.
- 15 Feb 2018 Planned primary completion date changed from 1 Feb 2019 to 1 Feb 2020.
- 14 Feb 2017 Planned End Date changed from 1 Feb 2016 to 1 Feb 2019.